IVX-411

IX-411
Vaccine description
Target	SARS-CoV-2
Vaccine type	Virus-like particles
Clinical data
Routes of; administration	Intramuscular

IVX-411 is a COVID-19 candidate nanoparticle vaccine under development by Icosavax currently undergoing a Phase I/II clinical trial in Australia. It was originally developed at the Institute of Protein Design (IPD) and the University of Washington School of Medicine, both based at the University of Washington.

In 2022 results were released that the RDB antigen component of the vaccine was unstable, which resulted in reduced potency.

References

↑ "ANZCTR - Registration". anzctr.org.au. Retrieved 18 August 2021.
↑ "Icosavax Initiates Phase 1/2 Trial of COVID-19 VLP Vaccine Candidate - Icosavax, Inc". investors.icosavax.com. Archived from the original on 30 October 2021. Retrieved 18 August 2021.
↑ "Two nanoparticle vaccines enter clinical trials". Institute for Protein Design. 2 June 2021. Retrieved 18 August 2021.
↑ Arunachalam PS, Walls AC, Golden N, Atyeo C, Fischinger S, Li C, et al. (June 2021). "Adjuvanting a subunit COVID-19 vaccine to induce protective immunity". Nature. 594 (7862): 253–258. Bibcode:2021Natur.594..253A. doi:10.1038/s41586-021-03530-2. PMID 33873199.
↑ "Icosavax Announces Results from IVX-411 Drug Product Investigation and Outlines Additional Corporate Milestones". BioSpace. 28 July 2022.

This article about COVID-19 vaccines is a stub. You can help Wikipedia by adding missing information.

This article about vaccines or vaccination is a stub. You can help Wikipedia by adding missing information.

[1] "ANZCTR - Registration". anzctr.org.au. Retrieved 18 August 2021.

[2] "Icosavax Initiates Phase 1/2 Trial of COVID-19 VLP Vaccine Candidate - Icosavax, Inc". investors.icosavax.com. Archived from the original on 30 October 2021. Retrieved 18 August 2021.

[3] "Two nanoparticle vaccines enter clinical trials". Institute for Protein Design. 2 June 2021. Retrieved 18 August 2021.

[4] Arunachalam PS, Walls AC, Golden N, Atyeo C, Fischinger S, Li C, et al. (June 2021). "Adjuvanting a subunit COVID-19 vaccine to induce protective immunity". Nature. 594 (7862): 253–258. Bibcode:2021Natur.594..253A. doi:10.1038/s41586-021-03530-2. PMID 33873199.

[5] "Icosavax Announces Results from IVX-411 Drug Product Investigation and Outlines Additional Corporate Milestones". BioSpace. 28 July 2022.